“Intellectually Smart Devices: Navigating Patent Risks in the Age of Intelligent Inhalers,” Respiratory Drug Delivery Europe 2019 (May 2019)
“The Myriad Appeal: Federal Circuit rules that isolated DNA sequences are patent eligible subject matter under § 101,” Lexology (August 2011)
“Description proscription? Ariad v. Lilly decision to be reviewed by full court,” Industrial Biotechnology (2009)
The Bright Side of Nuclear Winter: Opportunities in the New, New Economy,” xconomy.com (January 2009)
“Maximizing IP value in an economic downturn (& beyond) in the life science industry,” Industrial Biotechnology (2009)
Speaking engagements
“IPRs During The Pandemic: What Has Been Happening At The PTAB?” Consero IP Management Forum (October 22, 2021)
“Maximizing your IP Due Diligence Approach and How the Deal is Structured,” Momentum’s Due Diligence for Life Sciences (August 18, 2021)
“A View From The Trenches Of The PTAB: Strategies For Patent Owners (& Patent Applicants),” Consero 2019 Global IP Management Forum (December 2019)
“A View from the Tranches of the PTAB: Strategies for Patent Owners,” Consero 2019 Global IP Management Forum (June 2019)
“Intellectually Smart Devices: Navigating Patent Risks in the Age of Intelligent Inhalers” Respiratory Drug Delivery Europe 2019 (May 2019)
“Managing The Inside-Outside Counsel Working Relationship” Consero 2017 IP Forum for Life Sciences (April 2017)
“KnowledgeBridge: A View From The Trenches Of The Most-Active Forum For Patent Validity Challenges – The PTAB” Consero 2017 IP Forum for Life Sciences (April 2017)
“IP Perspectives – US and China Webinar Series: Cross-Border Patent Issues in the Life Sciences,” Fish Webinar (April 2017)
“Knowledge Bridge: A View From the Trenches of the Most Active Forum for Patent Validity Challenges—the PTAB,” Consero 2016 IP Forum for Life Sciences (December 2016)
“Biologics Litigation and IPRs,” Fish Webinar (October 2016)
“Three Years Post-AIA: What Have We Learned?,” Consero 2016 Global IP Management Forum (June 2016)
“PTAB Adjudication Process: Lessons Learned Over Three Years,” Thomas Jefferson School of Law IP Symposium: Aftershocks of the AIA’s Post-Grant Proceedings: Its Advocates & Critics (April 2016)
“Three Years After the AIA: What Have We Learned?,” Consero 2015 IP Forum for Pharmaceuticals and Biotechnology (December 2015)
“Advanced Strategies for Life Sciences Companies: IPR and FDA Regulatory Strategy,” Georgia Bio Innovation Summit (November 2015)
“Old Dog, New Tricks: Forward-Thinking Trends for the AIA,” Consero 2015 Global IP Management Forum (June 2015)
“Foreign Filing Strategies – Considerations in Protecting Your Patents Globally,” Fish Patent Webinar (February 2014)
“The Eternal Balancing Act: Protecting Your Global IP And Sticking To Budget,” Consero 2013 IP Pharma Summit (December 2013)
“Post-Grant for Practitioners Part IX: Inter Partes Review and the Life Sciences,” Fish Post-Grant Webinar (October 2013)
“Maximizing IP Due Diligence to Minimize Risk,” Consero 2013 Intellectual Property Management Forum (June 2013)
“First Inventor to File Under AIA,” Minneapolis Patents on Tap Series (March 2013)
“America Invents Act: Adapting to the New Rules,” Silicon Valley Life Sciences Series (March 2013)
“America Invents Act: Get Ready for the New Rules,” Boston Biotech Series (February 2013)
